跳到正文
原文
Nature 健康护理主题·· 2 天前AI 评分42

全球肝病登记系统的系统综述:设计、管理和可持续性实践

A systematic review of liver disease registries across the globe: design, management and sustainability practices

AI 导读

一项全球肝病登记系统的系统综述分析了其设计模式、管理机制和可持续性实践。研究涵盖了中国乙肝登记(CR-HepB)、中国急性慢性肝衰竭登记(CATCH-LIFE)、丹麦丙型肝炎登记及欧洲罕见肝病登记等多个实例,为肝病患者注册研究的规范化和持续发展提供参考。

正文
  1. Devarbhavi, H. et al. Global burden of liver disease: 2023 update. J. Hepatol. 79, 516–537 (2023).

    Article  PubMed  Google Scholar 

  2. Sarin, S. K. et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol. Hepatol. 5, 167–228 (2020).

    Article  PubMed  Google Scholar 

  3. Sun, J., Tanaka, J. & Valenti, L. The changing epidemiology of liver diseases in Asia. Liver Int. 42, 1926–1929 (2022).

    Article  PubMed  Google Scholar 

  4. Younossi, Z. M. et al. Clinical and patient-reported outcomes from patients with nonalcoholic fatty liver disease across the world: data from the global non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD) registry. Clin. Gastroenterol. Hepatol. 20, 2296–2306.e6 (2022).

    Article  PubMed  Google Scholar 

  5. Hoque, D. M. E., Sampurno, F., Ruseckaite, R., Lorgelly, P. & Evans, S. M. Study protocol of an equivalence randomized controlled trial to evaluate the effectiveness of three different approaches to collecting Patient Reported Outcome Measures (PROMs) data using the Prostate Cancer Outcomes Registry-Victoria (PCOR-VIC). BMC Health Serv. Res. 17, 75 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Pericleous, M., Kelly, C., Schilsky, M., Dhawan, A. & Ala, A. Defining and characterising a toolkit for the development of a successful European registry for rare liver diseases: a model for building a rare disease registry. Clin. Med. 22, 340–347 (2022).

    Article  Google Scholar 

  7. McGettigan, P. et al. Patient registries: an underused resource for medicines evaluation : operational proposals for increasing the use of patient registries in regulatory assessments. Drug Saf. 42, 1343–1351 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Nelson, E. C. et al. Patient focused registries can improve health, care, and science. BMJ 354, i3319 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Rubinger, L., Ekhtiari, S., Gazendam, A. & Bhandari, M. Registries: Big data, bigger problems?. Injury 54(Suppl 3), S39–S42 (2023).

    Article  PubMed  Google Scholar 

  10. Lazem, M. & Sheikhtaheri, A. Barriers and facilitators for disease registry systems: a mixed-method study. BMC Med. Inform. Decis. Mak. 22, 97 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Pop, B. et al. The role of medical registries, potential applications and limitations. Med. Pharm. Rep. 92, 7–14 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  12. Viviani, L., Zolin, A., Mehta, A. & Olesen, H. V. The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry. Orphanet J. Rare Dis. 9, 81 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  13. Vento, S. & Cainelli, F. Acute liver failure in low-income and middle-income countries. Lancet Gastroenterol. Hepatol. 8, 1035–1045 (2023).

    Article  PubMed  CAS  Google Scholar 

  14. Nario, S. et al. A nurse practitioner model of care in the era of direct acting antiviral therapy for hepatitis C virus infection. JGH Open 5, 669–672 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  15. Xu, X. Q. et al. Ten-year changes in clinical characteristics and antiviral treatment patterns of chronic hepatitis B in China: a CR-HepB-based real-world study. Zhonghua Gan Zang Bing. Za Zhi 31, 698–704 (2023).

    PubMed  PubMed Central  CAS  Google Scholar 

  16. Lau, F. F. et al. Ischemic heart disease in chronic hepatitis B: a Danish nationwide cohort study. Clin. Epidemiol. 14, 879–888 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  17. Lazarus, J. V. et al. European ‘NAFLD Preparedness Index’—is Europe ready to meet the challenge of fatty liver disease?. JHEP Rep. 3, 100234 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  18. Ornos, E. D., Murillo, K. J. & Ong, J. P. Liver diseases: perspective from the Philippines. Ann. Hepatol. 28, 101085 (2023).

    Article  PubMed  CAS  Google Scholar 

  19. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151, 264–269 (2009). W64.

    Article  PubMed  Google Scholar 

  20. Valizadeh, A. et al. Abstract screening using the automated tool Rayyan: results of effectiveness in three diagnostic test accuracy systematic reviews. BMC Med. Res. Methodol. 22, 160 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  21. Jiang, Z. G. et al. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease. Liver Int. 36, 1213–1220 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Jiang, Z. G. et al. Genetic determinants of circulating lipoproteins in nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 52, 444 (2018).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Shan, S. et al. China Registry of Hepatitis B (CR-HepB): protocol and implementation of a nationwide hospital-based registry of hepatitis B. Scand. J. Public Health 48, 233–239 (2020).

    Article  PubMed  Google Scholar 

  24. Shan, S. et al. Baseline characteristics and treatment patterns of the patients recruited to the china registry of hepatitis B. J. Clin. Transl. Hepatol. 7, 322–328 (2019).

    PubMed  PubMed Central  Google Scholar 

  25. Gu, W. Y. et al. Acute-on-chronic liver failure in China: rationale for developing a patient registry and baseline characteristics. Am. J. Epidemiol. 187, 1829–1839 (2018).

    Article  PubMed  Google Scholar 

  26. Qiao, L. et al. Cohort profile: a multicentre prospective validation cohort of the Chinese Acute-on-Chronic Liver Failure (CATCH-LIFE) study. BMJ open 11, e037793 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  27. Sølund, C. et al. Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation. Scand. J. Gastroenterol. 53, 849–856 (2018).

    Article  PubMed  Google Scholar 

  28. Sølund, C. et al. Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations. PLoS ONE 9, e113034 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  29. Hallager, S. et al. Liver-related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without sustained virologic response. CLEP 9, 501–516 (2017).

    Article  Google Scholar 

  30. Hallager, S. et al. Mortality rates in patients with chronic hepatitis C and cirrhosis compared with the general population: a Danish cohort study. J. Infect. Dis. 215, 192–201 (2017).

    PubMed  CAS  Google Scholar 

  31. Nielsen, S. et al. Hepatitis C prevalence in Denmark in 2016—an updated estimate using multiple national registers. PLoS ONE 15, e0238203 (2020).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Carr, B. I., Guerra, V., Donghia, R. & Yilmaz, S. Tumor multifocality and serum albumin levels can identify groups of patients with hepatocellular carcinoma and portal vein thrombosis having distinct survival outcomes. Ann. Med. Surg. 66, 102458 (2021).

    Article  CAS  Google Scholar 

  33. Hagström, H., Shang, Y., Wester, A. & Widman, L. Cohort profile: decoding the epidemiology of liver disease in Sweden (DELIVER). Scand. J. Gastroenterol. 57, 978–983 (2022).

    Article  PubMed  Google Scholar 

  34. Alexopoulos, A. et al. Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease. Hepatology 74, 1220–1233 (2021).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Hardy, T. et al. The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemp. Clin. Trials 98, 106175 (2020).

  36. Huber, Y. et al. Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin. Gastroenterol. Hepatol. 17, 2085–2092.e1 (2019).

    Article  PubMed  Google Scholar 

  37. McTeer, M. et al. Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information. PLoS ONE 19, e0299487 (2024).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Mann, J. P. et al. European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale. Contemp. Clin. Trials 75, 67–71 (2018).

    Article  PubMed  Google Scholar 

  39. Dakhoul, L. et al. Older age and disease duration are highly associated with hepatocellular carcinoma in patients with autoimmune hepatitis. Dig. Dis. Sci. 64, 1705–1710 (2019).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Hinrichsen, H. et al. Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry. Eur. J. Gastroenterol. Hepatol. 33, 415–423 (2020).

    Article  Google Scholar 

  41. Siederdissen et al. Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. United Eur. Gastroenterol. J. 6, 213–224 (2018).

    Article  Google Scholar 

  42. Tacke, F. et al. Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. Liver Int. 37, 205–211 (2017).

    Article  PubMed  CAS  Google Scholar 

  43. Hüppe, D. et al. The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R). J. Viral Hepat. 28, 1474–1483 (2021).

    Article  PubMed  Google Scholar 

  44. Christensen, S. et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?. Addiction 113, 868–882 (2018).

    Article  PubMed  Google Scholar 

  45. Christensen, S. et al. Alcohol and cannabis consumption does not diminish cure rates in a real-world cohort of chronic hepatitis C virus infected patients on opioid substitution therapy—data from the German Hepatitis C-Registry (DHC-R). Subst. Abuse Res. Treat. 13, 1178221819835847 (2019).

    Article  Google Scholar 

  46. Tacke, F. et al. Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: data from the German Hepatitis C-Registry. Hepatol. Commun. 6, 2488–2495 (2022).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Bischoff, J. et al. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry. HIV Clin. trials 19, 225–234 (2018).

    Article  PubMed  Google Scholar 

  48. Ohlendorf, V. et al. Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R). J. Viral Hepat. 28, 1206–1218 (2021).

    Article  PubMed  CAS  Google Scholar 

  49. Rau, M. et al. Prognostic impact of steatosis in the clinical course of chronic HCV infection-Results from the German Hepatitis C-Registry. PLoS ONE 17, e0264741 (2022).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Sarrazin, C. et al. Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015. Z. Gastroenterol. 57, 584–592 (2019).

    Article  PubMed  Google Scholar 

  51. Stein, K. et al. Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R). Eur. J. Gastroenterol. Hepatol. 34, 76–83 (2022).

    Article  PubMed  CAS  Google Scholar 

  52. Krüger, K. et al. Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry. Eur. J. Gastroenterol. Hepatol. 31, 230–240 (2019).

    Article  PubMed  Google Scholar 

  53. Bischoff, J. et al. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?. HIV Med. 19, 299–307 (2018).

    Article  PubMed  CAS  Google Scholar 

  54. Cornberg, M. et al. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment. Pharmacol. Ther. 45, 688–700 (2017).

    Article  PubMed  CAS  Google Scholar 

  55. Dultz, G. et al. Effectiveness and safety of direct-acting antiviral combination therapies for treatment of hepatitis C virus in elderly patients: results from the German Hepatitis C Registry. Drugs Aging 35, 843–857 (2018).

    Article  PubMed  CAS  Google Scholar 

  56. Wiegand, J. et al. Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register). Eur. J. Gastroenterol. Hepatol. 31, 1424–1431 (2019).

    Article  PubMed  CAS  Google Scholar 

  57. Weinmann, A. et al. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry. J. Clin. Gastroenterol. 48, 279–289 (2014).

    Article  PubMed  Google Scholar 

  58. Schmitt, A. et al. Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R). Z. Gastroenterol. 58, 341–351 (2020).

    Article  PubMed  Google Scholar 

  59. Younossi, Z. M. et al. Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver RegistryTM. J. Viral Hepat. 30, 335–344 (2023).

    Article  PubMed  CAS  Google Scholar 

  60. Yilmaz, Y. et al. Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study. Aliment. Pharmacol. Ther. 57, 215–223 (2023).

    Article  PubMed  CAS  Google Scholar 

  61. Tan, E. X. et al. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. Metab.: Clin. Exp. 126, 154911 (2022).

    Article  PubMed  CAS  Google Scholar 

  62. Harris, A. M. et al. Hepatitis B testing, care linkage, and vaccination coverage within a registry of hepatitis C infected patients. Vaccine 37, 2188–2193 (2019).

    Article  PubMed  Google Scholar 

  63. Børresen, M. L. et al. Hepatitis B prevalence and incidence in Greenland: a population-based cohort study. Am. J. Epidemiol. 181, 422–430 (2015).

    Article  PubMed  Google Scholar 

  64. Skladany, L. et al. Adherence to oral nutritional supplements after being discharged from the hospital is low but improves outcome in patients with advanced chronic liver disease. Patient Prefer. Adherence 14, 2559–2572 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  65. Skladany, L. et al. Frailty in nonalcoholic fatty liver cirrhosis: a comparison with alcoholic cirrhosis, risk patterns, and impact on prognosis. Can. J. Gastroenterol. Hepatol. 2021, 5576531 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  66. Skladany, L. et al. Applicability and prognostic value of frailty assessment tools among hospitalized patients with advanced chronic liver disease. Croatian Med. J. 62, 8–16 (2021).

    Article  Google Scholar 

  67. Skladaný, Ľ et al. Comparison of the quality of life of patients with liver cirrhosis before and during the COVID-19 lockdown in Slovakia. Sci. Rep. 13, 2463 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  68. DeSilva, M. B., Settgast, A., Chrenka, E., Kodet, A. J. & Walker, P. F. Improving care for patients with chronic hepatitis B via establishment of a disease registry. Am. J. Trop. Med. Hyg. 107, 198–203 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  69. Mokdad, A. A., Singal, A. G., Marrero, J. A., Zhu, H. & Yopp, A. C. Vascular invasion and metastasis is predictive of outcome in Barcelona clinic liver cancer stage C hepatocellular Carcinoma. J. Natl. Compr. Cancer Netw. 15, 197–204 (2017).

    Article  Google Scholar 

  70. Park, H. et al. Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection. Sci. Rep. 12, 18094 (2022).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. Reddy, K. R. et al. All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. Aliment. Pharmacol. Ther. 45, 115–126 (2017).

    Article  PubMed  CAS  Google Scholar 

  72. Younossi, Z. M. et al. Real-world outcomes of ledipasvir/sofosbuvir in treatment-naïve patients with hepatitis C. AJMC https://www.ajmc.com/view/real-world-outcomes-of-ledipasvir-sofosbuvir-in-treatment-naive-patients-with-hepatitis-c (2016).

  73. Abu-Dayyeh, I. et al. Patterns and trends of hepatitis C virus infection in Jordan: an observational study. Front. Public Health 11, 1280427 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  74. White, L. et al. Facilitating treatment of HCV in primary care in regional Australia: closing the access gap. Frontline Gastroenterol. 10, 210–216 (2019).

    Article  PubMed  Google Scholar 

  75. Gray, E. et al. Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection. J. Viral Hepat. 23, 677–686 (2016).

    Article  PubMed  CAS  Google Scholar 

  76. Gray, E., Pasta, D. J., Norris, S. & O’Leary, A. Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry. BMC Health Serv. Res. 17, 288 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  77. Pelizzaro, F. et al. Transarterial chemoembolization for hepatocellular carcinoma in clinical practice: temporal trends and survival outcomes of an iterative treatment. Front. Oncol. 12, 822507 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  78. Pelizzaro, F. et al. Monofocal hepatocellular carcinoma: How much does size matter?. Liver Int. 41, 396–407 (2021).

    Article  PubMed  CAS  Google Scholar 

  79. Pelizzaro, F. et al. Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients. Cancers 13, 897 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  80. Campani, C. et al. Time-varying mHAP-III is the most accurate predictor of survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Liver Cancer 10, 126–136 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  81. Bucci, L. et al. The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver Int. 37, 259–270 (2017).

    Article  PubMed  Google Scholar 

  82. Garuti, F. et al. The changing scenario of hepatocellular carcinoma in Italy: an update. Liver Int. 41, 585–597 (2021).

    Article  PubMed  Google Scholar 

  83. Giannini, E. G. et al. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. Digest. Liver Dis. 54, 1215–1221 (2022).

    Article  CAS  Google Scholar 

  84. Giannini, E. G. et al. Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice. Hepatology 67, 1784–1796 (2018).

    Article  PubMed  CAS  Google Scholar 

  85. Reggidori, N. et al. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs. JHEP Rep. 5, 100784 (2023).

  86. Cucchetti, A. et al. Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. Eur. J. Cancer 158, 100784 (2021).

    Article  Google Scholar 

  87. Trevisani, F. & Giannini, E. G. The ITA.LI.CA Consortium: How multicentre collaboration helped shape the management of patients with hepatocellular carcinoma on the basis of real-world evidence. Ann. Hepatol. 27(Suppl 1), 100564 (2022).

    Article  PubMed  Google Scholar 

  88. Fujii, H. et al. Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study. Clin. Gastroenterol. Hepatol. 21, 370–379 (2023).

  89. Kaze, E. & Henrion, J. 5-year mortality of alcohol-related cirrhosis: patients die just as much but not in the same manner. Acta Gastro-Enterol. Belg. 85, 370–379 (2022).

    Google Scholar 

  90. Kaze, E. & Henrion, J. Clinical characteristics of hepatocellular carcinoma in patients with cirrhosis: a comparative cohort study. Acta Gastro-Enterol. Belg. 86, 412–416 (2023).

    Article  CAS  Google Scholar 

  91. Yen, Y. H. et al. Real world clinical practice in treating advanced hepatocellular carcinoma: when East meets West. PLoS ONE 15, e0230005 (2020).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  92. Liu, Y.-W. et al. Prognosis after resection of single large hepatocellular carcinoma: results from an Asian high-volume liver surgery center. PLoS ONE 15, e0230897 (2020).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  93. Sinn, D. H., Gwak, G.-Y., Cho, J., Paik, S. W. & Yoo, B. C. Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort. PLoS ONE 9, e112184 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  94. Cho, H. J. et al. A proposal for modification of the barcelona clinic liver cancer staging system considering the prognostic implication of performance status. Gut liver 13, 557–568 (2019).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  95. Bessone, F. et al. Nitrofurantoin-induced liver injury: long-term follow-up in two prospective DILI registries. Arch. Toxicol. 97, 593–602 (2023).

    Article  PubMed  CAS  Google Scholar 

  96. Kudo, M. et al. Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver cancer 5, 190–197 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  97. Noronha, F. C. et al. Anticoagulation in cirrhosis and portal vein thrombosis is safe and improves prognosis in advanced cirrhosis. Dig. Dis. Sci. 64, 2671–2683 (2019).

    Article  Google Scholar 

  98. Allard, M. A. et al. Long-term outcomes of patients with 10 or more colorectal liver metastases. Br. J. Cancer 117, 604–611 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Viganò, L. et al. Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. a LiverMetSurvey-based study of 6,025 patients. Ann. Surg. Oncol. 21, 1276–1286 (2014).

    Article  PubMed  Google Scholar 

  100. Serenari, M. et al. The effect of a liver transplant program on the outcomes of resectable hepatocellular carcinoma: a nationwide multicenter analysis. Ann. Surg. 277, 664–671 (2023).

    Article  PubMed  Google Scholar 

  101. Famularo, S. et al. Machine learning predictive model to guide treatment allocation for recurrent hepatocellular carcinoma after surgery. JAMA Surg. 158, 192–202 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  102. Stvilia, K. et al. Hepatitis C treatment uptake among patients who have received methadone substitution treatment in the Republic of Georgia. Public health 195, 42–50 (2021).

    Article  PubMed  Google Scholar 

  103. Averhoff, F. et al. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia. J. Hepatol. 72, 680–687 (2020).

    Article  PubMed  CAS  Google Scholar 

  104. Docherty, M. et al. Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis. J. Am. Med. Inform. Assoc. 28, 1235–1241 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  105. Woreta, T. A. et al. Validation of the accuracy of the FASTTM score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. PLoS ONE 17, e0266859 (2022).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  106. Kleiner, D. E. et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw. open 2, e1912565 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  107. Puri, P. et al. Alcohol consumption is associated with the severity and outcome of acute liver injury/failure. Liver Int. 40, 360–367 (2020).

    Article  PubMed  CAS  Google Scholar 

  108. Rubin, J. B., Hameed, B., Gottfried, M., Lee, W. M. & Sarkar, M. Acetaminophen-induced acute liver failure is more common and more severe in women. Clin. Gastroenterol. Hepatol. 16, 936–946 (2018).

    Article  PubMed  CAS  Google Scholar 

  109. Camarata, M. A. et al. Outcomes of acute liver injury in adults due to Wilson’s disease: is survival without transplant possible?. Liver Transplant. 26, 330–336 (2020).

    Article  Google Scholar 

  110. Cardoso, F. S. et al. Persistent but not transient acute kidney injury was associated with lower transplant-free survival in patients with acute liver failure: a multicenter cohort study. Crit. Care Med. 50, 1329–1338 (2022).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  111. Rao, A. et al. Secular trends in severe idiosyncratic drug-induced liver injury in North America: an update from the Acute Liver Failure Study Group Registry. Am. J. Gastroenterol. 117, 617–626 (2022).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  112. Kendall, C. E. et al. A cross-sectional study of prolonged disengagement from clinic among people with HCV receiving care in a low-threshold, multidisciplinary clinic. Can. Liver J. 3, 212–223 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  113. Assal, A., Mackie, D. & Cooper, C. L. Transient elastography, APRI, and ultrasound have minimal utility in chronic low-replicative hepatitis B infection. Eur. J. Gastroenterol. Hepatol. 26, S25–S31 (2014).

    Article  Google Scholar 

  114. Alonso, E. M., James, L. P., Zhang, S. & Squires, R. H. Acetaminophen adducts detected in serum of pediatric patients with acute liver failure. J. Pediatr. Gastroenterol. Nutr. 61, 102–107 (2015).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  115. Huang, C. F. et al. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatol. Int. 13, 587–598 (2019).

    Article  PubMed  Google Scholar 

  116. Wong, Y. J. et al. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study. Hepatol. Int. 17, 1150–1161 (2023).

    Article  PubMed  Google Scholar 

  117. Okushin, K. et al. The impact of COVID-19 on the diagnosis and treatment of HCC: analysis of a nationwide registry for advanced liver diseases (REAL). Sci. Rep. 14, 2826 (2024).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  118. Okushin, K. et al. Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). J. Gastroenterol. 57, 587–597 (2022).

    Article  PubMed  CAS  Google Scholar 

  119. Curran, C., Stanley, A. J., Barclay, S. T., Priest, M. & Graham, J. The association between deprivation and the incidence and survival of patients with hepatocellular carcinoma in the West of Scotland. Expert Rev. Gastroenterol. Hepatol. 15, 1427–1433 (2021).

    Article  PubMed  CAS  Google Scholar 

  120. Osinubi, A. et al. Evaluation of the performance of algorithms that use serial hepatitis C RNA Tests to predict treatment initiation and sustained virological response among patients infected with hepatitis C virus. Am. J. Epidemiol. 188, 555–561 (2019).

    Article  PubMed  Google Scholar 

  121. Cabibbo, G. et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment. Pharmacol. Ther. 46, 688–695 (2017).

    Article  PubMed  CAS  Google Scholar 

  122. Lee, M. W. et al. Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma <3 cm: emphasis on association of local tumor progression and overall survival. Eur. Radiol. 30, 2391–2400 (2020).

    Article  PubMed  Google Scholar 

  123. Bae, B. K. et al. Trends in radiotherapy administration in the management of hepatocellular carcinoma: analysis of a Korean tertiary hospital registry of hepatocellular carcinoma patients diagnosed between 2005 and 2017. Front. Oncol. 12, 928119 (2022).

  124. Bae, B. K., Yu, J. I., Park, H. C., Goh, M. J. & Paik, Y. H. Radiotherapy trend in elderly hepatocellular carcinoma: retrospective analysis of patients diagnosed between 2005 and 2017. Radiat. Oncol. J. 41, 928119 (2023).

    Article  Google Scholar 

  125. Yu, J. I. et al. External validation of subclassification system and progression pattern analysis in hepatocelluar carcinoma with macroscopic vascular invasion. Radiother. Oncol. 187, 109841 (2023).

    Article  PubMed  Google Scholar 

  126. McDonald, S. A. et al. What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?. J. Hepatol. 62, 262–268 (2015).

    Article  PubMed  Google Scholar 

  127. McDonald, S. A. et al. Uptake of endoscopic screening for gastroesophageal varices and factors associated with variceal bleeding in patients with chronic hepatitis C infection and compensated cirrhosis, 2005-2016: a national database linkage study. Aliment. Pharmacol. Ther. 50, 425–434 (2019).

    Article  PubMed  CAS  Google Scholar 

  128. McAllister, G. et al. Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland. J. Clin. Virol. 61, 359–364 (2014).

    Article  PubMed  Google Scholar 

  129. Mustafa, M. Z. et al. The efficacy and safety of treating hepatitis C in patients with a diagnosis of schizophrenia. J. Viral Hepat. 21, e48–e51 (2014).

    Article  PubMed  CAS  Google Scholar 

  130. Valerio, H. et al. Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: implications for reinfection. Drug Alcohol Depend. 154, 125–131 (2015).

    Article  PubMed  Google Scholar 

  131. Robles-Diaz, M. et al. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 147, 109–118.e5 (2014).

    Article  PubMed  CAS  Google Scholar 

  132. Robles-Diaz, M. et al. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity. Liver Int. 35, 2474–2482 (2015).

    Article  PubMed  CAS  Google Scholar 

  133. Bessone, F. et al. Serious liver injury induced by Nimesulide: an international collaborative study. Arch. Toxicol. 95, 1475–1487 (2021).

    Article  PubMed  CAS  Google Scholar 

  134. Fernández, C. C. et al. Successful continuation of HCV treatment after liver transplantation. Transplantation 101, 1009–1012 (2017).

    Article  PubMed  Google Scholar 

  135. Fernández, C. C. et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the Hepa-C registry. Hepatology 65, 1810–1822 (2017).

    Article  PubMed  Google Scholar 

  136. Xu, L. et al. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. J. Gastroenterol. Hepatol. 30, 1032–1039 (2015).

    Article  PubMed  CAS  Google Scholar 

  137. Engstrand, J., Stål, P., Gilg, S., Jansson, A. & Strömberg, C. Hepatocellular carcinoma in cirrhotic versus non-cirrhotic liver: treatment and survival differences in a nationwide cohort. Scand. J. Surg. 113, 120–130 (2024).

    Article  PubMed  Google Scholar 

  138. Alswat, K. et al. Clinical and metabolic characteristics of non-alcoholic fatty liver disease patients in Saudi Arabia: data from the Systematic Observatory Liver Disease (SOLID) Registry. Diabetes Metab. Syndr. Obes. 14, 1167–1175 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  139. Yu, M. L. et al. An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan. Hepatol. Int. 18, 461–475 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  140. Lu, M.-Y. et al. Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: a nationwide hepatitis C virus registry program. Clin. Mol. Hepatol. 30, 64–79 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  141. Chang, T. S. et al. Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry. Hepatol. Int. 17, 550–561 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  142. Chen, C. et al. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: a real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int. 41, 1265–1277 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  143. Huang, C. F. et al. Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: a large cohort study from the nationwide HCV registry program (TACR). Clin. Gastroenterol. Hepatol. 20, 1151–1162.e6 (2022).

    Article  PubMed  CAS  Google Scholar 

  144. Lo, C. C. et al. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: real-world evidence from a nationwide registry in Taiwan. J. Formos. Med. Assoc. 121, 1567–1578 (2022).

    Article  PubMed  CAS  Google Scholar 

  145. Chang, I. C. et al. The hepatitis viral status in patients with hepatocellular carcinoma: a study of 3843 patients from Taiwan Liver Cancer Network. Medicine 95, e3284 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  146. Barritt, A. S. et al. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: the TARGET-NASH study. Contemp. Clin. trials 61, 33–38 (2017).

    Article  PubMed  Google Scholar 

  147. Chirapongsathorn, S. et al. Characteristics of drug-induced liver injury in chronic liver disease: results from the Thai Association for the Study of the Liver (THASL) DILI Registry. J. Clin. Transl. Hepatol. 11, 88–96 (2023).

    PubMed  Google Scholar 

  148. Thanapirom, K. et al. Association of the S267F variant on NTCP gene and treatment response to pegylated interferon in patients with chronic hepatitis B: a multicentre study. Antivir. Ther. 23, 67–75 (2018).

    Article  PubMed  CAS  Google Scholar 

  149. Drysdale, K. et al. English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed. Aliment. Pharmacol. Ther. 52, 168–181 (2020).

    Article  PubMed  CAS  Google Scholar 

  150. Schmeltzer, P. A. et al. Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int. 36, 603–609 (2016).

    Article  PubMed  CAS  Google Scholar 

  151. Mahale, P. et al. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut 67, 553–561 (2018).

    Article  PubMed  CAS  Google Scholar 

  152. El-Serag, H. B., Kanwal, F., Davila, J. A., Kramer, J. & Richardson, P. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology 146, 1249–55.e1 (2014).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  153. El-Serag, H. B., Kramer, J., Duan, Z. & Kanwal, F. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J. viral Hepat. 23, 687–696 (2016).

    Article  PubMed  CAS  Google Scholar 

  154. Rabiee, A. et al. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. Hepatol. Commun. 7, e0093 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  155. Kaplan, D. E. et al. Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database. Clin. Gastroenterol. Hepatol. 13, 2333–2341 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  156. Iluz-Freundlich, D. et al. Spontaneous flares of chronic hepatitis b virus in hepatitis be antigen negative carriers who subsequently clear hepatitis B surface antigen. Dig. Dis. Sci. 66, 257–262 (2021).

    Article  PubMed  CAS  Google Scholar 

  157. Attia, D. et al. Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based study. Aliment. Pharmacol. Ther. 56, 1581–1590 (2022).

    Article  PubMed  CAS  Google Scholar 

  158. Wang, H. et al. Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis. J. Viral Hepat. 25, 930–938 (2018).

    Article  PubMed  CAS  Google Scholar 

  159. Wyber, R. et al. Big data in global health: improving health in low- and middle-income countries. Bull. World Health Organ. 93, 203–208 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  160. Stanaway, J. D. et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388, 1081–1088 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  161. Oni, T. et al. Global public health starts at home: upstream approaches to global health training. Lancet Glob. Health 7, e301–e302 (2019).

    Article  PubMed  Google Scholar 

  162. Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).

    Article  PubMed  Google Scholar 

  163. Jaacks, L. M. et al. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol. 7, 231–240 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  164. Kostkova, P. et al. Who owns the data? Open data for healthcare. Front. Public Health 4, 7 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  165. Jawhari, B., Ludwick, D., Keenan, L., Zakus, D. & Hayward, R. Benefits and challenges of EMR implementations in low resource settings: a state-of-the-art review. BMC Med. Inform. Decis. Mak. 16, 116 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  166. van Panhuis, W. G. et al. A systematic review of barriers to data sharing in public health. BMC Public Health 14, 1144 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  167. Tiangco, B. et al. Challenges in the maintenance of an open hospital-based cancer registry system in a low-to-middle-income country (LMIC): 2017-2022 experience. PLOS Digit. Health 3, e0000328 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  168. Tan, A. L., Feliciano, E. J. G., Habaluyas, K. E. R., Bolong, N. P. & Wong, J. Q. Processes of creating a national cancer registry system in the Philippines. Electron. J. Inf. Syst. Dev. Ctries. 90, e12324 (2024).

    Article  Google Scholar 

  169. Macrohon, B. C. et al. The design and development of a national registry of pediatric neurological diseases in the Philippines—a preliminary report. Philipp. J. Neurol. 21, 20–29 (2018).

    Google Scholar 

  170. Gliklich, R. E., Leavy, M. B. & Dreyer, N. A. Registries for Evaluating Patient Outcomes: A User’s Guide. (Agency for Healthcare Research and Quality (US), 2020).

  171. Farhan, M. et al. National hepatitis registry in Pakistan: a dire need for hepatitis surveillance and control. Trop. Med. Health 51, 41 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  172. Najibah, N. et al. Designing a mobile app for a national liver cancer registry in Bangladesh. in Lecture Notes in Computer Science 329–346 (Springer Nature Switzerland, 2025).

  173. Danford, C. J. et al. A pathophysiologic approach combining genetics and insulin resistance to predict the severity of nonalcoholic fatty liver disease. Hepatol. Commun. 2, 1467–1478 (2018).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  174. Zhang, M. et al. ‘Treat-all’ strategy for patients with Chronic Hepatitis B virus infection in China: are we there yet?. J. Clin. Transl. Hepatol. 12, 589–593 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  175. Christensen, P. B. et al. Hepatitis C prevalence in Denmark—an estimate based on multiple national registers. BMC Infect. Dis. 12, 178 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  176. Akkiz, H. et al. Macroscopic portal vein thrombosis in HCC patients. Can. J. Gastroenterol. Hepatol. 2018, 3120185 (2018).

    PubMed  PubMed Central  Google Scholar 

  177. Michel, M. et al. Lower incidence of HCC and other major adverse liver outcomes in people living with HIV and chronic liver disease. Gastro Hep Adv. 3, 783–792 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  178. ClinicalTrials.gov. Study record NCT04442334. https://clinicaltrials.gov/study/NCT04442334.

  179. Health Research Authority. European Paediatric NAFLD Registry (EU-PNAFLD). https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/european-paediatric-nafld-registry-eu-pnafld/.

  180. Global Liver Council. Global Liver Registry. https://www.globallivercouncil.org/global-liver-registry/.

  181. Global NASH Council. Global NASH Council. https://www.globalnashcouncil.org/.

  182. Yopp, A. C. et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann. Surg. Oncol. 21, 1287–1295 (2014).

    Article  PubMed  Google Scholar 

  183. HCV-TARGET—Hepatitis C Therapeutic Registry and Research Network. Study record. https://ctv.veeva.com/study/hcv-target-hepatitis-c-therapeutic-registry-and-research-network.

  184. Sumida, Y. et al. Non-invasive scoring systems for predicting NASH in Japan: evidences from Japan Study Group of NAFLD. Integr. Mol. Med. 2, 145–149 (2015).

    Google Scholar 

  185. Bessone, F. et al. Drug-induced liver injury in Latin America: 10-year experience of the Latin American DILI (LATINDILI) Network. Clin. Gastroenterol. Hepatol. 23, 89–102 (2025).

    Article  PubMed  CAS  Google Scholar 

  186. Viganò, L. LiverMetSurvey registry: The Italian experience. in Surgical Treatment of Colorectal Liver Metastases 165–182 (Springer Milan, 2011).

  187. NASH Clinical Research Network (NASH CRN). NASH Clinical Research Network. https://gastroenterology.ucsd.edu/research/labs/fatty-liver/research/epidemiology/nash-crn.html.

  188. Reuben, A. et al. Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study. Ann. Intern. Med. 164, 724–732 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  189. Acute Liver Failure Study Group. https://labs.utsouthwestern.edu/acute-liver-failure-study-group/research.

  190. Lepage, C. et al. Telemedicine successfully engages marginalized rural hepatitis C patients in curative care. J. Assoc. Med. Microbiol. Infect. Dis. Can. 5, 87–97 (2020).

    PubMed  PubMed Central  Google Scholar 

  191. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Study Repository. https://repository.niddk.nih.gov/study/45.

  192. Cartabellotta, F., Di Marco, V. & RESIST - HCV The HCV Sicily Network: a web-based model for the management of HCV chronic liver diseases. Eur. Rev. Med. Pharmacol. Sci. 20, 11–16 (2016).

    PubMed  CAS  Google Scholar 

  193. Calvaruso, V. et al. Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. J. Viral Hepat. 28, 1190–1199 (2021).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  194. Sinn, D. H. et al. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS ONE 10, e0124434 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  195. Public Health Scotland. Scottish Hepatitis C Virus (HCV) Clinical Database. https://publichealthscotland.scot/resources-and-tools/health-intelligence-and-data-management/national-data-catalogue/national-datasets/search-the-datasets/scottish-hepatitis-c-virus-hcv-clinical-database/.

  196. Spanish DILI Registry. Herramientas Para Colaborar. https://www.spanishdili.uma.es/index.php/colaborar/herramientas-para-colaborar.

  197. Swedish Quality Registry Group for Liver, Bile Duct and Gallbladder Cancer. National Quality Registry Group—Liver, Bile Ducts And Gallbladder Cancer. https://cancercentrum.se/samverkan/cancerdiagnoser/lever-och-galla/kvalitetsregister/registergrupp/.

  198. Abdo, A. A. et al. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann. Saudi Med. 32, 174–199 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  199. SOLID Registry. SOLID—Liver Registry. https://www.solid-registry.com/home%20from.

  200. TARGET-NASH. TARGET-NASH Registry. https://www.targetrwe.com/unique-data/registries/target-nash/.

  201. UK Department of Health and Social Care. Hepatitis C National Register. https://www.gov.uk/government/publications/hepatitis-c-national-register.

  202. Chalasani, N. et al. Drug induced liver injury network (DILIN) prospective study. Am. J. Gastroenterol. 101, S169 (2006).

    Article  Google Scholar 

  203. Drug-Induced Liver Injury Network (DILIN). DILIN. Available from: https://dilin.org/.

  204. John, B. V. et al. Liver stiffness measurement and risk prediction of hepatocellular carcinoma after HCV eradication in veterans with cirrhosis. Clin. Gastroenterol. Hepatol. 22, 778–788.e7 (2024).

    Article  PubMed  Google Scholar 

  205. Van Iderstine, M. G., Uhanova, J. & Minuk, G. Y. Liver enzymes and fibrosis markers in patients with non-alcoholic fatty liver disease and concomitant chronic viral hepatitis. Can. Liver J. 4, 317–321 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

来源:Nature 健康护理主题 · nature.com